The estimated Net Worth of Adrian Haigh is at least $1.34 Million dollars as of 19 April 2024. Mr. Haigh owns over 44,445 units of Fennec Pharmaceuticals Inc stock worth over $116,893 and over the last 6 years he sold FENC stock worth over $1,096,878. In addition, he makes $124,152 as Independent Director at Fennec Pharmaceuticals Inc.
Adrian has made over 3 trades of the Fennec Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 44,445 units of FENC stock worth $102,668 on 19 April 2024.
The largest trade he's ever made was selling 88,888 units of Fennec Pharmaceuticals Inc stock on 17 April 2024 worth over $536,884. On average, Adrian trades about 20,202 units every 0 days since 2018. As of 19 April 2024 he still owns at least 22,223 units of Fennec Pharmaceuticals Inc stock.
You can see the complete history of Mr. Haigh stock trades at the bottom of the page.
Adrian J. Haigh serves as Independent Director of the Company. Previously Mr. Haigh served as Chief Operating Officer at Gentium GmbH since March 2011. Prior to joining Gentium, Mr. Haigh served as Regional VP Commercial Operations at Biogen Idec where he managed several affiliates and also the global distributor business and prior to that was the General Manager of Amgen Nordis and Portugal. He served as the Executive Vice President of Global Marketing and Corporate Planning at EUSA Pharma and joined EUSA from Amgen where he led the international oncology franchise. Mr. Haigh previously has held senior commercial and marketing positions at SmithKline Beecham, Schering Plough, Organon and Novo Nordisk. He has been a Director of Fennec Pharmaceuticals Inc. since April 28, 2014 and a Director at Arch Biopartners Inc. since August 21, 2014. He received a Bachelor of Arts with Honors in Economic History from Huddersfield Polytechnic, West Yorkshire, England and a Diploma in Marketing from the Institute of Marketing. As a result of these and other professional experiences, Mr. Haigh has extensive international oncology development expertise which strengthens the Board’s collective qualifications, skills and experience.
As the Independent Director of Fennec Pharmaceuticals Inc, the total compensation of Adrian Haigh at Fennec Pharmaceuticals Inc is $124,152. There are 8 executives at Fennec Pharmaceuticals Inc getting paid more, with Rostislav Raykov having the highest compensation of $1,477,140.
Adrian Haigh is 56, he's been the Independent Director of Fennec Pharmaceuticals Inc since 2014. There are 4 older and 5 younger executives at Fennec Pharmaceuticals Inc. The oldest executive at Fennec Pharmaceuticals Inc is Anne McKay, 67, who is the Regulatory Consultant.
Over the last 10 years, insiders at Fennec Pharmaceuticals Inc have traded over $13,607,192 worth of Fennec Pharmaceuticals Inc stock and bought 1,966,488 units worth $9,890,813 . The most active insiders traders include Management Pr, Llcmancheste..., Spacavazza Paolo Cavazza En..., and Rosty Raykov. On average, Fennec Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $442,734. The most recent stock trade was executed by Rosty Raykov on 31 August 2024, trading 2,431 units of FENC stock currently worth $13,419.
fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
Fennec Pharmaceuticals Inc executives and other stock owners filed with the SEC include: